<DOC>
	<DOCNO>NCT02261714</DOCNO>
	<brief_summary>The purpose study investigate effect TG01 Granulocyte macrophage colony stimulate factor ( GM-CSF ) give addition gemcitabine ( chemotherapy ) - Understand possible side effect additional use TG01/GM-CSF gemcitabine - Investigate whether TG01/GM-CSF give gemcitabine produce immune response - Investigate treatment delay reduce recurrence disease</brief_summary>
	<brief_title>Antigen-specific Cancer Immunotherapy ( TG01 ) Gemcitabine Adjuvant Therapy Resected Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis adenocarcinoma pancreas 2 . Stage I II disease ( clinical stage T13 , N01 , M0 AJCC stag criterion ) . 3 . Successful surgical resection Complete resection ( R0 ) microscopic residual disease ( R1 ) Expected receive gemcitabine monotherapy adjuvant chemotherapy 4 . Laboratory Values : Absolute neutrophil count ≥ 1.5 x 10^9/l Platelets ≥100 x 10^9/l Haemoglobin ≥ 9 g/dl Total bilirubin ≤ 1.5 x UNL Serum creatinine ≤ 1.5 x UNL Albumin ≥ 2.5 g/dl AST ALT ≥ 5 x UNL 5 . 18 year age old . 6 . ECOG performance status ( PS ) 01 . 7 . Life expectancy least 6 month 8 . Men woman childbearing potential must willing use effective method contraception prevent pregnancy 9 . Provide write ( sign ) inform consent participate trial prior trial specific screening procedure 1 . Has receive investigational drug within 4 week prior Trial drug administration 2 . Has receive previous therapy pancreatic cancer include radiation chemotherapy ( except primary resection primary neoadjuvant chemotherapy ) . 3 . Is currently receive agent know effect immune system , unless dose level immunosuppressive ( e.g . Prednisone 10 mg/day less inhaled steroid dos use treatment asthma ) . 4 . Has serious illness medical condition , limit : Any uncontrolled infection Uncontrolled cardiac failure classification III IV ( NY Heart Association ) Uncontrolled systemic gastrointestinal inflammatory condition Bone marrow dysplasia History autoimmune disease History adverse reaction vaccine 5 . Known history positive test HIV/AIDS , hepatitis B C 6 . Pregnant lactating female pregnancy test baseline ( postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential ) . 7 . Contraindication gemcitabine treatment 8 . Have malignancy within last 3 year ( except adequately treat carcinoma cervix basal squamous cell skin cancer ) 9 . Known malignant brain lesion ( ) 10 . Are unlikely start chemotherapy within 12 week surgery ( e.g . delay wound healing , infection , etc . ) 11 . Are expect complete 6 cycle chemotherapy 12 . Are planned receive yellow fever live ( attenuate ) vaccine course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pancreatic cancer , resect</keyword>
	<keyword>Vaccine</keyword>
	<keyword>KRAS</keyword>
</DOC>